Suicidal Behavior and Depression in Smoking Cessation Treatments
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Two treatments for smoking cessation--varenicline and bupropion--carry Boxed Warnings from the U.S. Food and Drug Administration (FDA) about suicidal/self-injurious behavior and depression. However, some epidemiological studies report an increased risk in smoking or smoking cessation independent of treatment, and differences between drugs are unknown. METHODOLOGY: From the FDA's Adverse Event Reporting System (AERS) database from 1998 through September 2010 we selected domestic, serious case reports for varenicline (n = 9,575), bupropion for smoking cessation (n = 1,751), and nicotine replacement products (n = 1,917). A composite endpoint of suicidal/self-injurious behavior or depression was defined as a case with one or more Preferred Terms in Standardized MedDRA Query (SMQ) for those adverse effects. The main outcome measure was the ratio of reported suicide/self-injury or depression cases for each drug compared to all other serious events for that drug. RESULTS: Overall we identified 3,249 reported cases of suicidal/self-injurious behavior or depression, 2,925 (90%) for varenicline, 229 (7%) for bupropion, and 95 (3%) for nicotine replacement. Compared to nicotine replacement, the disproportionality results (OR (95% CI)) were varenicline 8.4 (6.8-10.4), and bupropion 2.9 (2.3-3.7). The disproportionality persisted after excluding reports indicating concomitant therapy with any of 58 drugs with suicidal behavior warnings or precautions in the prescribing information. An additional antibiotic comparison group showed that adverse event reports of suicidal/self-injurious behavior or depression were otherwise rare in a healthy population receiving short-term drug treatment. CONCLUSIONS: Varenicline shows a substantial, statistically significant increased risk of reported depression and suicidal/self-injurious behavior. Bupropion for smoking cessation had smaller increased risks. The findings for varenicline, combined with other problems with its safety profile, render it unsuitable for first-line use in smoking cessation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They found a higher number of reports of suicidality/self-injurious behavior among patients using NRTs (N = 50) compared to those using antibiotics (N = 21).”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, both varenicline and bupropion were observed to have far higher numbers of individuals who experienced suicidal ideation (N = 1135 and N = 73), attempts (N = 323 and N = 56), behaviors (N = 63 and N = 1), and completions (N = 272 and N = 19) than individuals who were taking NRTs.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In their evaluation of case reports of adverse events reported to the FDA, Moore et al.28 found that the odds ratio for suicide was elevated for bupropion compared to the antibiotic comparison group (OR: 12.5; CI: 9.1–17.2).”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moore et al.28 found that 90% of the 3,249 FDA-reported cases of suicidal/self-injurious behavior or depression associated with smoking cessation pharmacotherapies were found in individuals taking varenicline. This included 272 (92%) of the reported completed suicides and 323 (85%) of all reported suicide attempts.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“However, the evidence supporting their conclusion is somewhat limited, as they did not include a comparison group of individuals attempting to quit smoking without any pharmacotherapy.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders ( DSM ‐ IV ‐ TR )
Segal, D. L. (2010) · The Corsini Encyclopedia of Psychology · doi:10.1002/9780470479216.corpsy0271 · Cited by 4,666
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,464 · cited 1×
“Treatment Efficacy The efficacy of the three major pharmacological interventions for smoking cessation has been studied in numerous randomized clinical trials [33,34].”
Background(2010) · PsycEXTRA Dataset · doi:10.1037/e590462011-001 · Cited by 1,803
Nicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“adverse event data that escape detection in clinical trials because of their rarity or uncertain event ascertainment [24–27].”
BackgroundEffects of abstinence from tobacco: Valid symptoms and time course
Hughes, J. (2007) · Nicotine & Tobacco Research · doi:10.1080/14622200701188919 · Cited by 801 · cited 1×
“These reports provided stronger evidence for other withdrawal symptoms such as irritability, insomnia, and weight gain, [8–10] which suggests that depression is not common in nicotine withdrawal.”
ResultAubin, H.-J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B., Gong, J., Williams, K. E., & Reeves, K. R. (2008) · Thorax · doi:10.1136/thx.2007.090647 · Cited by 344 · cited 1×
“The only published trial comparing varenicline to nicotine patches found no statistically significant difference in reported 7-day abstinence at 52 weeks [37].”
BackgroundPharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
Eisenberg, M. J., Filion, K. B., Yavin, D., Belisle, P., Mottillo, S., Joseph, L., Gervais, A., O'Loughlin, J., Paradis, G., Rinfret, S., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070256 · Cited by 318 · cited 1×
“Treatment Efficacy The efficacy of the three major pharmacological interventions for smoking cessation has been studied in numerous randomized clinical trials [33,34].”
BackgroundSingh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110218 · Cited by 286
Self-citationThe Global Research Neglect of Unassisted Smoking Cessation: Causes and Consequences
Chapman, S., & MacKenzie, R. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000216 · Cited by 237 · cited 1×
“Retrospective studies of successful quitters often favor self quitters or cold turkey approaches [35].”
Background
Research works printed but not linked: 2
- Josefberg H 2006 Clinical Safety Review Application 21-928 Varenicline tartrate Silver Spring, MD U.S. Food and Drug Administration, Center for Drug Evaluation and Research
- Winchell C 2006 Supervisory Review of NDA: Safety Review and Primary Clinical Efficacy Review Varenicline Pfizer Inc.U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Cited by
Items 101–155 of 155
Thomas, K. H., Caldwell, D. M., Dalili, M. N., Gunnell, D., Munafo, M. R., Stevenson, M., & Welton, N. J. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015414 · Cited by 4
Assessing combined effects of varenicline and N‐acetylcysteine on reducing nicotine seeking in rats
Nall, R. W., Beloate, L. N., Meyerink, M. E., Penaloza, T., Doolittle, J. D., Froeliger, B., Kalivas, P. W., & García‐Keller, C. (2022) · Addiction Biology · doi:10.1111/adb.13151 · Cited by 5
Risikofaktor „Rauchen“: Wege aus der Nikotinsucht bei Patienten mit kardiovaskulären Erkrankungen
Weil, J., Stritzke, J., & Schunkert, H. (2011) · Der Internist · doi:10.1007/s00108-011-2892-6 · Cited by 9
Assessing Psychiatric Adverse Effects during Clinical Drug Development
Rudorfer, M. V., & Hillefors, M. (2012) · Pharmaceutical Medicine · doi:10.1007/bf03262382 · Cited by 3
Ascher, J. A., Stemhagen, A., Stender, M., Win, B., & Winter, C. (2018) · Drugs - Real World Outcomes · doi:10.1007/s40801-018-0140-2 · Cited by 3
Olawale, M. E., & Lazarus, P. J. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103792 · Cited by 4
An Update on Somatic Treatments for Suicide Risk
Rizk, M., & Mann, J. J. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260287 · Cited by 4
Mocking, R. J. T., Wever, S. A., Pflanz, C. P., Pringle, A., Parsons, E., McTavish, S. F. B., Cowen, P. J., Harmer, C. J., & Schene, A. H. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3213-7 · Cited by 4
“Despite its effectiveness, varenicline use decreased because of reported associations with depression and suicidal ideation, leading to an FDA-boxed warning (Moore et al. 2011).”
BackgroundResultInfluentialTalukder, S. R., Lappin, J., Boland, V. C., Weaver, N., McRobbie, H. J., & Courtney, R. J. (2024) · Addictive Behaviors · doi:10.1016/j.addbeh.2024.108148 · Cited by 4
The Safety of Generic Prescription Drugs in the United States
Singh, S. (2018) · Drug Safety · doi:10.1007/s40264-017-0632-0 · Cited by 4
“identify suicide in the FAERS database, where identification of suicide is challenging [15].”
BackgroundSelf-citationVarenicline and evaluated outcomes in smoking cessation programmes
Santus, P., Bassi, L., Airoldi, A., Giovannelli, F., & Radovanovic, D. (2015) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2013.105 · Cited by 2
Ledford, C. J. W. (2013) · Communication Quarterly · doi:10.1080/01463373.2013.799508 · Cited by 3
Wu, I.-H., Chen, H., Bordnick, P. S., Essien, E. J., Johnson, M. L., Peters, R. J., Wang, X., & Abughosh, S. (2016) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2016.08.001 · Cited by 2
“…et al., Comparison of Suicide Attempts/Behaviors Following Smoking Cessation Treatments Among Schizophrenic Smokers, Archives of Psychiatric Nursing (2016), http://dx.doi.org/10.1016/j.apnu.2016.08.001 serious suicidal/self injurious side effects for Varenicline and Bupropion (Moore et al., 2011).”
BackgroundInfluentialTreatment of Depression in a Former Smoker With Varenicline? A Case Report and Discussion
Kausch, O. (2014) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.13030045 · Cited by 2
A Need for Personalised Suicidology: Pharmacoepidemiology
Tournier, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-26282-6_32 · Cited by 2
Riyadi, S., Yati, D., & Lutfiyati, A. (2018) · Wiraraja Medika Jurnal Kesehatan · doi:10.24929/fik.v8i1.504 · Cited by 2
Kageyama, K., Sato, M., Ito, S., Ino, Y., Nakao, S., Bunchuailua, W., Rungpragayphan, S., Krichanchai, S., Iguchi, K., Ishiguro, M., et al. (2026) · Psychiatry Research Communications · doi:10.1016/j.psycom.2026.100250 · Cited by 1
Profiling adverse drug events of cancer drug ingredients using normalized AERS data
Wang, L., & Liu, H. (2013) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2013.6732599 · Cited by 1
Varenicline and Risk of Self-Harm: A Nested Case-Control Study
Tadrous, M., Martins, D., Yao, Z., Mamdani, M., Juurlink, D. N., Gomes, T., & Antoniou, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163681 · Cited by 1
Aggravation of Acute Adrenal Crisis Due to Varenicline in a Patient with Adrenal Insufficiency
Turan, E., Turan, Y., Savut, B., Kulaksızoğlu, M., & Karakurt, F. (2016) · Endocrinology research and practice. · doi:10.4274/tjem.3088 · Cited by 1
Risikofaktor "Rauchen" Wege aus der Nikotinsucht bei Patienten mit kardiovaskulären Erkrankungen
Schleswig-Holstein, U., & Lübeck, C. (2012) · Cited by 1
Ghamri, R. A. (2018) · Journal of Substance Use · doi:10.1080/14659891.2018.1489010 · Cited by 2
“Nevertheless, Moore et al. (2011) noted 3,249 reported cases of depression or suicide according to the Adverse Event Reporting System database of the US Food and Drug Administration from 1998 to 2010, of which 90% were related to varenicline use.”
BackgroundVarenicline (Chantix): The Smoking Cessation Medication Prescribers May Be Avoiding
Mills, J. (2022) · Issues in Mental Health Nursing · doi:10.1080/01612840.2022.2061806 · Cited by 1
“One of the most frequently cited articles on this consumer data had strong language for varenicline, asserting it was not safe enough to be a first-line option (Moore et al., 2011).”
BackgroundHanewinkel, R., Isensee, B., & Morgenstern, M. (2012) · Der Pneumologe · doi:10.1007/s10405-011-0557-8 · Cited by 1
Lico, R., Ling, Y., & Jaiswal, S. K. (2021) · Neuroscience & Medicine · doi:10.4236/nm.2021.122006 · Cited by 1
Pharmacological therapies in smoking cessation: an evidence-based update
Allam, J. S., & Ochoa, C. (2015) · Current Pulmonology Reports · doi:10.1007/s13665-015-0125-5
Pharmaceutical Product Development and Liability With Chantix®: A Teaching Case
Wells, B. P. (2015) · Risk Management and Insurance Review · doi:10.1111/rmir.12037
Varenicline: the risks of over-the-counter sales in Brazil
Zaparoli, J. X., & Galduróz, J. C. F. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-1107
Smoking Cessation Among Methadone Users In Mauritius
RN, B., & Roland, G. (2014) · IOSR Journal of Nursing and health Science · doi:10.9790/1959-03333241
Effects of smoking and smoking cessation on mental disorders
Noda, T. (2016) · The Japanese Journal of Health Psychology · doi:10.11560/jahp.28.special_issue_129
Medications Used in Smoking Cessation and Alcohol Use Disorders
(2013) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814343664_0018
Bylund, K. (2012) · ResearchWorks at the University of Washington (University of Washington)
More Bad News About Varenicline
Krumholz, H. M., & Sm (2011) · Journal watch · doi:10.1056/jc201112070000001
Loddenkemper, R. (2012)
Zhang, J. (2017) · TSpace (University of Toronto) · Cited by 1
Gysling, E. (2011) · pharma-kritik · doi:10.37667/pk.2011.854
Brown, B. R. (2013) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)
BMJ Publishing Group Ltd (2012) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2011.02.0077
Medrano, J. F. F. (2012) · Revista de la Asociación Española de Neuropsiquiatría · doi:10.4321/s0211-57352012000300013
Schippert, D. W., & Rechtine, G. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40030-5.00176-3
(2017) · Wiley eBooks · doi:10.1002/9781119183839.refs
The withdrawal of drugs from the market as a result of post-authorisation pharmacovigilance
Dobrek, Ł. (2022) · Farmacja Polska · doi:10.32383/farmpol/153052
Truong, V. T. T., Green, C., Pedroza, C., Hwang, L., Rajan, S. S., Suchting, R., Cinciripini, P. M., Tyndale, R. F., & Lerman, C. E. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-01931-7 · Cited by 2
Harrigan, M. R., & Deveikis, J. P. (2023) · Contemporary medical imaging · doi:10.1007/978-3-031-45598-8_16
Rahmawati, S., Arslan, Z., Börekçi, Ş., Gemicioğlu, B., & Türkmen, Z. (2024) · Annales de Toxicologie Analytique · doi:10.1016/j.toxac.2024.11.015
Jeong, C., Kim, B., Oh, D. J., Sohn, T. S., Han, K., & Kwon, H.-S. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112967 · Cited by 2
Acute Ischaemic Stroke Agnieszka Anna Ardelt
Harrigan, M. R., Deveikis, J. P., & Ardelt, A. A. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-946-4_17
Pharmacotherapy for Nicotine and Tobacco Use Disorders
Abdelrahman, A. (2026) · Springer eBooks · doi:10.1007/978-3-031-57159-6_59-1
Approche thérapeutique et cognitive chez les patients souffrant d'une addiction au tabac
Vanderkam, P. (2023) · theses.fr (ABES) · doi:10.70675/307f9e53z9985z46a6z8c9dz1701c02f2849
An Update for Varenicline (Chantix) in 2026: Still Effective and Still Safe
Mills, J. (2026) · Issues in Mental Health Nursing · doi:10.1080/01612840.2026.2679935 · Cited by 1
“…varenicline for two decades now comes from the FDA’s 2009 boxed warning on the agent that warned about risks of serious neuropsychiatric events and suicidal ideation or suicidal behavior, added after worrisome user reports surfaced in the FDA’s Adverse Event Reporting System (Moore et al., 2011).”
BindingDB (2014) · UC San Diego · doi:10.7270/q2jw8gbv
Metadata
- Authors
- Moore, T. J., Furberg, C. D., Glenmullen, J., Maltsberger, J. T., & Singh, S.
- Affiliations
- Institute for Safe Medication Practices (US)
- Wake Forest University Health Sciences (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Corresponding author
- Moore, Thomas J.
- ORCID
- Singh, Sonal
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-11-02
- Volume
- 6
- Issue
- 11
- Pages
- e27016
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3206890
- OpenAlex
- W2081459939
- Cited by
- 150
- References
- 29
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 11 · 2017: 10 · 2016: 17 · 2015: 11 · 2014: 9 · 2013: 30 · 2012: 27
- FWCI
- 15.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- smoking cessation, varenicline, bupropion, nicotine replacement therapy, suicidal behavior, self-harm, depression, adverse drug reactions, drug safety, FDA boxed warning, disproportionality analysis, serious adverse events
- MeSH terms
- Varenicline, Adult, Benzazepines, Depression, Female, Humans, Male, Middle Aged, Nicotine, Quinoxalines, Suicide, Smoking Cessation, Bupropion, Nicotinic Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

